The agency is proposing drugmakers use shorter nonrodent studies and other sources of evidence when developing monoclonal antibodies for non-cancer settings.
The study will test the therapy in lung, colorectal, and head and neck cancer patients with B7H3 and PTK7 mutations.
The company is evaluating EN-374 in patients with X-linked chronic granulomatous disease as part of a Phase I/II trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback